Placebo News and Research

RSS

Viewpoints: Michelle Nunn's confusing stance on health law; seeking to assess Wis. wxperiment

In Georgia, where the Republican Senate primary takes place today, the early campaign season has been spent with the candidates vying to out-conservative each other.

22 May 2014

Phase 3 data of VIVACITO study evaluating effect of T+O FDC in COPD presented at ATS conference

Boehringer Ingelheim today presented results of the VIVACITO® (NCT01559116) study, the first Phase 3 data to be reported from the TOviTO® clinical trial program, evaluating the effect of the fixed-dose combination of tiotropium and olodaterol (T+O FDC) delivered via the Respimat® inhaler on lung function in people with chronic obstructive pulmonary disease (COPD).

22 May 2014

Physiotherapy for hip osteoarthritis questioned

Hip osteoarthritis is a prevalent and costly chronic musculoskeletal condition. Clinical guidelines recommend physiotherapy as treatment, although its effectiveness has never been proven.

22 May 2014

Researchers explore perceptions of cancer trials on ‘International Clinical Trials Day’

A new article published by ecancermedicalscience on May 20th addresses the question of why cancer patients are afraid of participating in potentially life-saving clinical trials.

21 May 2014

Edison Pharmaceuticals' EPI-743 granted orphan designation for Leigh syndrome in Japan

Edison Pharmaceuticals has announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted Orphan Designation to EPI-743 for the treatment of Leigh syndrome.

21 May 2014

New antibody can improve quality of life for individuals with asthma

Researchers at St. Joseph's Healthcare Hamilton and McMaster University have successfully tested an antibody that can improve the quality of life for individuals with asthma by relieving inflammation in the lungs.

21 May 2014

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).

21 May 2014

Aradigm receives QIDP designation for its inhaled antibiotic candidate, Pulmaquin

Aradigm Corporation (the "Company") today announced that the U.S. Food and Drug Administration (FDA) has designated the Company's lead inhaled antibiotic candidate, Pulmaquin®, as a Qualified Infectious Disease Product (QIDP).

20 May 2014

Sanofi presents Phase II trial results for investigational vaccine for prevention of CDI

Sanofi Pasteur, the vaccines division of Sanofi, presented Phase II (H-030-012) trial results for an investigational vaccine for the prevention of Clostridium difficile infection at the 114th General Meeting of the American Society for Microbiology.

20 May 2014

Novel drug for patients with inoperable CTEPH shows improvement in international trial

After a year of being treated with a novel drug, patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) and those with persistent or recurrent pulmonary hypertension after an operation for the disease showed sustained improvement in a multicenter, international trial presented at the 2014 American Thoracic Society International Conference.

20 May 2014

Juventas presents positive trial results of JVS-100 drug delivered by Biocardia’s Helix transendocardial system

BioCardia®, Inc., a leader in cardiovascular regenerative medicine, today announced the presentation by Juventas Therapeutics of their positive four-month results for their STOP-HF Trial.

20 May 2014

GSK reports positive results from Incruse Ellipta and Advair Diskus combination therapy in COPD patients

GlaxoSmithKline plc today presented data at the American Thoracic Society (ATS) from a late-stage clinical study.

20 May 2014

Study compares effectiveness of duloxetine and fluoxetine in children with MDD

Two studies of the anti-depressive drug duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), compared its effectiveness and safety to either fluoxetine or placebo in children and adolescents with major depressive disorder (MDD).

20 May 2014

Ring pessary for OAB as effective as nonsurgical therapies

The use of a ring pessary appears to be an effective, well tolerated and inexpensive treatment for overactive bladder, say US researchers writing in International Urogynecology Journal.

19 May 2014

Vandetanib delays disease progression in elderly NSCLC patients

Vandetanib used in combination with gemcitabine significantly improves progression-free survival compared with gemcitabine alone when used as a first-line treatment for elderly patients with advanced non-small-cell lung cancer, Italian researchers report.

19 May 2014

Researchers identify drugs to slow progression of idiopathic pulmonary fibrosis

Researchers in separate clinical trials found two drugs slow the progression of idiopathic pulmonary fibrosis, a fatal lung disease with no effective treatment or cure, and for which there is currently no therapy approved by the Food and Drug Administration.

19 May 2014

Endo acquires worldwide rights to Zogenix' sumatriptan injection

Endo International plc announced today that affiliates of the company have completed the acquisition of worldwide rights to Sumavel® DosePro® (sumatriptan injection), a needle-free delivery system for subcutaneous use, from Zogenix, Inc, for $85 million in cash and rights to additional cash payments based on the achievement of certain commercial milestones.

19 May 2014

Convenient new treatment option for rheumatoid arthritis sufferers offers patient freedom and control of disease

A new subcutaneous formulation of RoActemra® (tocilizumab) has today been launched providing thousands of UK rheumatoid arthritis (RA) patients with a potentially life-changing treatment option.1

19 May 2014

Phase III INPULSIS trials show nintedanib slows disease progression in patients with IPF

Results from the Phase III INPULSIS™ trials, published online today in the New England Journal of Medicine, show nintedanib significantly slowed disease progression in patients with idiopathic pulmonary fibrosis (IPF).

19 May 2014

Vitamin D shown to have limited benefit for asthma

Adding vitamin D to asthma treatment to improve breathing only appears to benefit patients who achieve sufficient levels of the supplement in the blood. Overall, the ability to control asthma did not differ between a study group that received vitamin D supplements and a group that received placebo, according to new research at Washington University School of Medicine in St. Louis.

19 May 2014

Placebo News and Research

Viewpoints: Michelle Nunn's confusing stance on health law; seeking to assess Wis. wxperiment

Phase 3 data of VIVACITO study evaluating effect of T+O FDC in COPD presented at ATS conference

Physiotherapy for hip osteoarthritis questioned

Researchers explore perceptions of cancer trials on ‘International Clinical Trials Day’

Edison Pharmaceuticals' EPI-743 granted orphan designation for Leigh syndrome in Japan

New antibody can improve quality of life for individuals with asthma

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Aradigm receives QIDP designation for its inhaled antibiotic candidate, Pulmaquin

Sanofi presents Phase II trial results for investigational vaccine for prevention of CDI

Novel drug for patients with inoperable CTEPH shows improvement in international trial

Juventas presents positive trial results of JVS-100 drug delivered by Biocardia’s Helix transendocardial system

GSK reports positive results from Incruse Ellipta and Advair Diskus combination therapy in COPD patients

Study compares effectiveness of duloxetine and fluoxetine in children with MDD

Ring pessary for OAB as effective as nonsurgical therapies

Vandetanib delays disease progression in elderly NSCLC patients

Researchers identify drugs to slow progression of idiopathic pulmonary fibrosis

Endo acquires worldwide rights to Zogenix' sumatriptan injection

Convenient new treatment option for rheumatoid arthritis sufferers offers patient freedom and control of disease

Phase III INPULSIS trials show nintedanib slows disease progression in patients with IPF

Vitamin D shown to have limited benefit for asthma

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News